Gujarat Terce Laboratories Ltd

On 19-Dec, Gujarat Terce Laboratories Ltd witnessed a notable rise in its share price, climbing 5.85% to close at ₹48.15, reflecting a strong short-term performance despite a challenging year-to-date and one-year backdrop.

Guj. Terce Labs has experienced a decline in net sales and profitability over the past three years, culminating in a loss of -2.52 Cr in the most recent fiscal year, with significant decreases in revenue and operating profit. The company's financial metrics indicate ongoing challenges in generating cash from core operations.

As of November 17, 2025, Guj. Terce Labs. is considered very expensive and overvalued, with a PE ratio of -32.23 and poor stock performance, significantly lagging behind peers like Sun Pharma and Divi's Lab.

Guj. Terce Labs has experienced a decline in net sales and profitability over the past three years, culminating in a loss of 2.52 Cr in the most recent fiscal year. However, there has been a notable recovery in cash flow activities in the latest fiscal year.

Gujarat Terce Laboratories' latest Q2 FY26 results are concerning, showing flat revenue growth and a significant decline in operating profit margins and net profit, indicating serious operational challenges and weak market confidence. The company's financial health is further stressed by high employee costs and a fully pledged promoter stake.

As of 06-Nov, Gujarat Terce Laboratories Ltd's stock price is Rs 44.15, down 3.73%, and has significantly underperformed with a 47.94% decline year-to-date, contrasting sharply with the Sensex's 6.62% gain. The stock is trading below key moving averages and has seen a drastic drop in investor interest, with delivery volume down 83.32% against the 5-day average.

As of 30-Oct, Gujarat Terce Laboratories Ltd's stock price is Rs 47.15, down 2.98%, with a significant year-to-date decline of 44.40%. Despite underperforming compared to the benchmark Sensex, there has been a 40.33% increase in delivery volume, indicating some investor interest.

As of 24-Oct, Gujarat Terce Laboratories Ltd's stock price is Rs 50.00, down 5.27%, with a significant intraday low of Rs 49.02. Despite a 2.04% gain over the past week, it has a year-to-date decline of 41.04%, indicating underperformance compared to the broader market.

As of 23-Oct, Gujarat Terce Laboratories Ltd's stock price is Rs 53.00, up 3.31% recently, with strong short-term gains but significant long-term declines of 37.50% year-to-date and 30.26% over the past year. Despite recent outperformance against the Sensex, the stock has faced pressure in the longer term, contrasting with its impressive three and five-year returns.

As of 17-Oct, Gujarat Terce Laboratories Ltd's stock price is Rs 48.11, up 4.22% today after three days of decline, but it has dropped 43.27% year-to-date. Despite a recent positive trend, the stock has underperformed compared to the Sensex, which has gained 7.44% this year.

As of 16-Oct, Gujarat Terce Laboratories Ltd's stock price has declined to Rs 46.16, down 13.96%, with significant recent underperformance and reduced investor participation. Despite long-term gains, the stock is facing a challenging environment marked by high volatility and a year-to-date decline of 45.57%.

As of 15-Oct, Gujarat Terce Laboratories Ltd's stock price is declining at 53.65, down 1.54% and has fallen 5.18% over the last two days. Despite strong long-term returns, the year-to-date performance is -36.73%, with reduced trading volume indicating decreased investor interest.

As of 13-Oct, Gujarat Terce Laboratories Ltd's stock price has risen to Rs 57.00, up 14.41%, with a strong performance over the past week and month, despite a year-to-date decline. The stock has shown impressive long-term gains, significantly outperforming the benchmark Sensex.

As of 10-Oct, Gujarat Terce Laboratories Ltd's stock price has risen to Rs 49.82, up 18.03%, showing strong performance and increased investor confidence despite a year-to-date decline of 41.25%. The stock significantly outperformed the benchmark Sensex, indicating a positive shift in market sentiment.